Learn More
BACKGROUND Appropriately timed cessation of chemotherapy is integral to patient's quality of life. We evaluate the use of and associated factors with chemotherapy at the end of life. METHODS A review of deceased oncology patients treated with palliative intent from April 2005 over 2 years at two cancer centres was carried out. Chi-square tests of patient(More)
BACKGROUND The selection criteria for phase III trials are often stringent. We aimed to determine how many advanced non-small-cell lung cancer (NSCLC) patients would have been eligible for phase III targeted therapy trials and the proportion receiving anticancer treatment. PATIENTS AND METHODS From March 2007 to May 2008, all advanced NSCLC patients(More)
OBJECTIVES To describe the clinical characteristics and outcomes of patients with severe acute respiratory syndrome (SARS). METHODS Between March 28 and June 30 '2003, 29 patients with probable SARS seen at Shin Kong Wu Ho-Su Memorial Hospital, Taipei, were analysed. RESULTS Presenting symptoms included fever (100%), cough (69.0%), chills or rigor(More)
Background:Although the prognosis of most patients presenting with malignant pleural mesothelioma (MPM) is poor, a small proportion survives long term. We investigated factors associated with survival in a large patient series.Methods:All patients registered with the NSW Dust Diseases Board (2002–2009) were included in an analysis of prognostic factors(More)
Pemetrexed is a multi-targeted anti metabolite that inhibits several key folate-dependent enzymes in the thymidine and purine biosynthetic pathways, including thymidylate synthase. It is currently approved for use in patients with non-small cell lung cancer and malignant mesothelioma. The sporadic and unpredictable occurrence of haematological toxicities of(More)
BACKGROUND The silent epidemic of mesothelioma in Australia is steadily increasing, and 30% of cases occur in New South Wales (NSW). AIM To describe the patterns of care and outcomes of patients with malignant pleural mesothelioma (MPM) in NSW. METHODS MPM patients in NSW applying for compensation at the NSW Dust Diseases Board from 2007 to 2009 were(More)
Bendifallah S, Uzan C, Fauvet R, Morice P, Darai E (2013) External multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours. Br J Cancer 109: 2774–2777. Iasonos A, Schrag D, Raj GV, Panageas KS (2008) How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26: 1364–1370. Obermair A(More)
10545 Background: Survival after EPP is variable. Currently there are no validated prognostic factors that can be used to select patients for this procedure. We have investigated the expression of calretinin and D2-40, both associated with tumour differentiation, as well as NLR, an index of systemic inflammatory response as potential preoperative prognostic(More)
BACKGROUND Immunotherapy agents show anti-cancer activity in several solid cancers. Efficacy in non-melanoma solid tumours for non-approved indications is unknown. AIM To evaluate patient and disease characteristics, rate and duration of response, and toxicity of self-funded pembrolizumab in patients with non-melanoma solid cancers. METHOD Retrospective(More)
  • 1